Saladax Biomedical Inc. (SBI)

65 articles about Saladax Biomedical Inc. (SBI)

• Saladax Biomedical, Inc. Acquires Intellectual Property Portfolio for Antipsychotic Drug Tests

  4/5/2022

  Saladax Biomedical, Inc. is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV.

• Saladax Biomedical, Inc. Announces Global Distribution Agreement With Beckman Coulter, Inc. for Antipsychotic Drug Tests

  3/15/2022

  Saladax Biomedical, Inc. (Saladax) is pleased to announce the signing of a global distribution agreement with Beckman Coulter, Inc. to distribute the MyCare™ Psychiatry Laboratory Assays. The MyCare™ Psychiatry Laboratory Assays measure drug levels of the antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as such as Schizophrenia and Bipolar Disorder.

• Saladax Biomedical and HLS Therapeutics Strengthen Partnership With an Exclusive Distribution Agreement for Canada

  11/18/2021

  Saladax Biomedical, Inc (Saladax) is pleased to announce an exclusive distribution agreement with HLS Therapeutics Inc. (“HLS”) (TSX:HLS) to distribute five MyCare™ Psychiatry Laboratory Assays used to measure the six most commonly prescribed antipsychotic drugs in Canada.

• Saladax Biomedical Announces Health Canada Approval of Five MyCare™ Psychiatry Laboratory Diagnostic Assay

  2/16/2021

  Saladax Biomedical, Inc. (Saladax) is pleased to announce the approval of five MyCare™ Psychiatry Laboratory Assays by Health Canada for use in measuring drug levels in patients prescribed any of the six most common antipsychotic drugs.

• Saladax Biomedical launches clozapine test in the US after FDA grants market authorization

  7/8/2020

  Saladax Biomedical Inc., announced that the FDA has granted their De Novo Request for a rapid blood test that measures clozapine levels in psychiatric patients.

• AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s Proprietary Platform Globally

  5/4/2020

  Fully automated immunoassay kit designed to simplify and streamline busulfan therapeutic drug monitoring (TDM), potentially reducing turnaround time from hours to minutes and greatly expanding hospital, clinic, medical office and laboratory access to TDM

• Saladax Develops First-Ever Rapid Test for an Antipsychotic Drug Using a Single Drop of Blood to Aid Psychiatrists in the Treatment of Schizophrenia

  9/5/2019

  Saladax Biomedical today announced that its MyCare Insite Clozapine Test is now CE marked for use on the MyCare Insite.

• Saladax Biomedical Launches Game-Changing Assays for Psychotherapeutics at AACC 2018

  7/25/2018

  ​Saladax is Advancing Personalized Medicine by Providing Psychiatrists with the New MyCare Line of Assays to Improve Patient Treatment.

• Saladax Submits for FDA Review a Rapid Blood Test for Levels of Risperidone

  7/17/2018

  Saladax Biomedical Inc., a diagnostics company providing kits to test drug blood levels for adherence and personalized dose management, on July 3 submitted a De Novo classification request to the U.S. Food and Drug Administration (FDA) for the MyCare Psychiatry™ Total Risperidone Assay Kit.

• Saladax Signs Licensing Agreement with Janssen for Antipsychotic Drug Testing Patents

  6/26/2018

  Saladax Biomedical Inc, Inc., a diagnostics company providing kits to measure drug blood levels for adherence and medication management, has signed a license agreement with Janssen Pharmaceutical, NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement Saladax acquired the worldwide exclusive patent rights for diagnostic tests that determine drug levels in patients undergoing treatment with antipsychotic medications.

• Saladax Receives Approval to Sell a New Line of Psychiatry Tests on the European Market

  3/21/2018

  Saladax is Advancing Personalized Medicine by Providing Doctors with Tests for Drug Levels to Better Treat Patients

• Saladax Biomedical Inc. (SBI) Is Awarded "Best Poster Presentation" For Study On Individualized Dosing Of Paclitaxel

  10/11/2017

• Saladax Biomedical Inc. (SBI) Release: Company Licenses Alzheimer’s Diagnostic Tests To Siemens Healthineers

  1/18/2017

• Saladax Biomedical Inc. (SBI) Release: Recent Study Shows Chemotherapy Toxic Effects Reduced Through Personalized Dosing

  11/15/2016

• ASCO15: Saladax Biomedical Inc. (SBI) Announces Presentation Of CEPAC-TDM Study Of Paclitaxel In Non-Small Cell Lung Cancer At 2015 ASCO Meeting

  6/9/2015

• Saladax Biomedical Inc. (SBI) Announces Presentation Of CEPAC-TDM Study Of Paclitaxel In Non-Small Cell Lung Cancer At 2015 ASCO Meeting

  6/8/2015

• Saladax Biomedical Inc. (SBI) Announces U.S. Launch Of MyImatinib Chemotherapy Exposure Optimization Test

  12/1/2014

• Fosun Pharma Launches Saladax Biomedical Inc. (SBI)'s MyCare Dosing Assays In China

  8/27/2014

• Saladax Biomedical Inc. (SBI) Announces U.S. Launch of MyCare&#0153 Portfolio of Chemotherapy Exposure Optimization Tests

  6/20/2013

• Saladax Biomedical Inc. (SBI) Receives CLIA Laboratory Certification and Approval to Begin Clinical Laboratory Operations in Support of MyCare&#0153 Portfolio

  6/10/2013